Another clinical study utilizing DEC-205 antibodies conjugated to NY-ESO-1 co-administered with the immune adjuvant PIC and decitabine chemotherapy detected NY-ESO-1-specific CD4+ and CD8+ T cells associated with the presence of CD141+ cDC1s in AML and myelodysplastic syndrome patients [137]. This evidence concerns the gene THBD and acute myeloid leukemia.